Extension Study to Evaluate the Long-term Efficacy and Safety of Everolimus in Liver Transplant Recipients
Status:
Completed
Trial end date:
2013-05-03
Target enrollment:
Participant gender:
Summary
The reason for this extension is to evaluate the long-term safety and efficacy of two
concentration-controlled everolimus regimen in de novo liver transplant recipients. The most
important long-term safety assessments include evaluation of renal function, progression of
HCV related allograft fibrosis, and other treatment related effects at Month 36
post-transplantation compared to extension baseline (Months 24 post-transplantation).